| Drug Type Small molecule drug | 
| Synonyms ICM | 
| Target | 
| Action inhibitors | 
| Mechanism HMGB1 inhibitors(High Mobility Group Protein B1 inhibitors), HMGB2 inhibitors(high mobility group box 2 inhibitors), KEAP1 inhibitors(Kelch-like ECH-associated protein 1 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC21H19N3O4 | 
| InChIKeyVVOXDJYPDCSQMI-UHFFFAOYSA-N | 
| CAS Registry908568-01-4 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Parkinson Disease | Preclinical | South Korea  | 01 Jan 2024 | |
| Parkinson Disease | Preclinical | South Korea  | 01 Jan 2024 | |
| Epilepsy | Preclinical | China  | 19 Apr 2023 | |
| Epilepsy | Preclinical | South Korea  | 19 Apr 2023 | |
| Neuroinflammation | Preclinical | South Korea  | 12 Oct 2014 | 





